LabCorp Extends Offer for Orchid Cellmark | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Laboratory Corporation of America has extended its tender offer to acquire all of the outstanding shares of Orchid Cellmark until 5:00 p.m., New York City time, on July 15, 2011.

The offer had been scheduled to expire on June 15. Last month, LabCorp received a request from the US Federal Trade Commission seeking additional information for its review of the $85.4 million acquisition.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.